Why Pharma Needs Validated Software From Vendors, Not Internally Vibe-Coded Apps

A widely cited MIT study published in July 2025, “The GenAI Divide: State of AI in Business 2025,” analyzed 300 public AI deployments alongside executive interviews and a survey of business leaders. Its headline finding was stark: 95% of AI pilots delivered no measurable financial impact. The more useful finding for a validation or quality leader deciding how to actually build with AI was this: tools built with an external vendor succeeded roughly twice as often as tools built internally, with one analysis putting the gap at 67% deployment success for vendor partnerships versus 33% for internal builds.

That statistic should reframe a conversation a lot of pharma and life sciences companies are having right now about “vibe coding.”

The promise of vibe coding, and where it runs out in a GxP environment

AI can generate a working application faster than any team has ever been able to build one. In most industries, that’s a large part of the test: does it work? Ship it, see if it’s useful, iterate.

In a GxP environment, “it works” is where the real work starts, not where it ends. Software that touches a validated system, a batch record, a deviation, or any GxP-regulated process has to be validated itself before it can be trusted with that role. It has to withstand a cybersecurity review. It has to hold up under 21 CFR Part 11 and GAMP 5 expectations for electronic records and risk-based assurance. It has to satisfy ALCOA+ data integrity principles, survive procurement and quality unit scrutiny, maintain a real audit trail, and come with an actual commitment to ongoing support and revalidation as the system changes. None of that comes from a prompt, no matter how good the resulting code is.

This is exactly what the MIT numbers are pointing at, even though the study wasn’t written about pharma specifically. An internally vibe-coded tool has working code and little else: no one has mapped it to GAMP 5’s risk categories, no one has built the change control process a quality unit would expect to see, no one is contractually on the hook for keeping it validated as it evolves. A vendor platform built for regulated environments has usually already been through some version of that gauntlet before it ever reaches a customer’s validation team, which is a large part of why it deploys successfully twice as often.

What “validated” actually buys a quality or validation team that “it works” doesn’t

Code is one piece of the equation. What doesn’t come from an AI prompt, however capable the model, is accountability for that code, a documented approach to risk-based validation, a real answer for an inspector asking about the current validated state of the system, or the accumulated trust a quality unit places in a platform that supports a regulated process.

A validated vendor platform carries that weight so an internal team doesn’t have to reinvent it, control by control. Someone has already answered who’s accountable when something breaks. Someone has already built the audit trail, the data integrity controls, and the documented validation approach an inspector actually expects to see, mapped to GAMP 5 and Part 11 from the start rather than retrofitted onto a tool that was never built with them in mind.

AI versus validated software is the wrong frame

The interesting version of this isn’t AI replacing validated systems. It’s AI raising what a validated system is expected to deliver. A platform that combines AI-native speed with the risk-based assurance, audit trail, and data integrity controls a GxP environment actually requires is a higher bar than either a legacy validated tool or a fast internal prototype clears on its own.

The real opportunity for pharma, biotech, and medical device organizations isn’t replacing validated systems with AI-generated ones. It’s using AI to strip out the administrative burden inside validation and quality work, speed up the genuinely mechanical parts of a gap assessment or a protocol, and free quality and validation staff to focus on the judgment calls that still need a human, all without giving up the controls that let the organization pass an inspection.

The takeaway

The companies that win the next decade of this shift in pharma won’t be the ones that generate the most code the fastest. They’ll be the ones that combine AI’s speed with a platform actually built, and validated, to carry the weight of a GxP-regulated process. AI is changing how software gets built. It isn’t changing what an inspector needs to see before trusting it.